New Delhi: Drug firm Sun Pharmaceutical Industries today said it has received final approval from the US health regulator for its generic Repaglinide tablets used for treatment of diabetes. The company is eligible for a 180-day marketing exclusivity in the US as its subsidiary is the first-to-file an abbreviated new drug applications (ANDA) for the product with a para IV certification, it added. United States Food and Drug Administration (USFDA) has granted final approval to company`s subsidiary for its ANDA for generic version of Repaglinide tablets in the strengths of 1 mg and 2 mg, Sun Pharma said in a statement.
INS Kuthar mishap: Navy orders probe
TRAI Amendment Bill passed in Lok Sabha
Govt slaps $579 mn additional penalty on RIL
UPSC aspirants protest outside Rajnath Singh`s residence